NAS:AMPH (USA) Also trade in: Germany

Amphastar Pharmaceuticals Inc

$ 20.56 0.29 (1.43%)
Volume: 98,912 Avg Vol (1m): 174,603
Market Cap $: 967.68 Mil Enterprise Value $: 990.75 Mil
P/E (TTM): 411.20 P/B: 3.08
Earnings Power Value -3.45
Net Current Asset Value 0.4
Tangible Book 5.81
Projected FCF 5.54
Median P/S Value 20.33
Graham Number 2.56
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 7/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 1.37
Cash-To-Debt ranked lower than
59.84% of 859 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 91151, Med: 2.03, Min: -0.01
AMPH: 1.37
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.97, Med: 1.53, Max: 2.13
Current: 1.37
0.97
2.13
Equity-to-Asset 0.62
Equity-to-Asset ranked higher than
62.18% of 788 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1.78, Med: 0.64, Min: -27.83
AMPH: 0.62
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: 0.62, Med: 0.73, Max: 0.77
Current: 0.62
0.62
0.77
Debt-to-Equity 0.18
Debt-to-Equity ranked higher than
71.31% of 596 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 31.22, Med: 0.32, Min: 0.01
AMPH: 0.18
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: 0.11, Med: 0.15, Max: 0.19
Current: 0.18
0.11
0.19
Debt-to-EBITDA 4.63
Debt-to-EBITDA ranked lower than
100.00% of 495 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 343059.67, Med: 1.92, Min: 0.01
AMPH: 4.63
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -14.14, Med: 1.24, Max: 10.61
Current: 4.63
-14.14
10.61
Piotroski F-Score 7
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 4.39
DISTRESS
GREY
SAFE
Beneish M-Score -2.18
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC -0.21%
WACC 8.08%

Profitability & Growth : 3/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -0.61
Operating Margin ranked lower than
72.78% of 801 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 8950, Med: 7.97, Min: -232970.37
AMPH: -0.61
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -28.29, Med: -2.19, Max: 13.45
Current: -0.61
-28.29
13.45
Net Margin % 0.74
Net Margin ranked lower than
70.95% of 802 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 304900, Med: 5.32, Min: -216285.19
AMPH: 0.74
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -5.08, Med: 2.69, Max: 8.86
Current: 0.74
-5.08
8.86
ROE % 0.71
ROE ranked lower than
67.19% of 832 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 316.96, Med: 5.94, Min: -3119.47
AMPH: 0.71
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -4.01, Med: 1.1, Max: 15.5
Current: 0.71
-4.01
15.5
ROA % 0.48
ROA ranked lower than
65.44% of 871 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 943.36, Med: 2.88, Min: -1851.14
AMPH: 0.48
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -2.94, Med: 0.83, Max: 11.4
Current: 0.48
-2.94
11.4
ROC (Joel Greenblatt) % -1.75
ROC (Joel Greenblatt) ranked lower than
67.84% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 34233.33, Med: 11.23, Min: -2671900
AMPH: -1.75
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -8.69, Med: 0.94, Max: 29.15
Current: -1.75
-8.69
29.15
3-Year Total Revenue Growth Rate 5.40
3-Year Revenue Growth Rate ranked lower than
71.12% of 689 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 291.9, Med: 5.8, Min: -100
AMPH: 4.3
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: -42.8, Med: -30.3, Max: 4.3
Current: 4.3
-42.8
4.3
3-Year Total EBITDA Growth Rate 20.80
3-Year EBITDA Growth Rate ranked lower than
100.00% of 704 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 299.6, Med: 7.3, Min: -343.2
AMPH: 19.6
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: 0, Med: -45.3, Max: 69.1
Current: 19.6
0
69.1
3-Year EPS w/o NRI Growth Rate -26.00
3-Year EPS w/o NRI Growth Rate ranked lower than
100.00% of 663 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 385.8, Med: 8.9, Min: -403.2
AMPH: -26
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: 0, Max: -26
Current: -26
0
-26

» AMPH's 30-Y Financials

Financials (Next Earnings Date: 2019-08-08)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:AMPH

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS : 325412    SIC : 2834
Compare XKRX:041960 SHSE:600993 SZSE:300401 ISX:SIDO SZSE:002219 XKRX:003520 SZSE:300723 TSXV:OGI NAS:RDUS SHSE:603456 TSE:4569 ROCO:6446 HKSE:02552 SZSE:300702 SZSE:002550 XBRU:MITRA SZSE:300110 SHSE:600750 TPE:1707 SZSE:002750
Traded in other countries 29A.Germany
Address 11570 6th Street, Rancho Cucamonga, CA, USA, 91730
Amphastar Pharmaceuticals Inc is a specialty pharmaceutical company engaged in developing, manufacturing, marketing and selling generic and proprietary injectable & inhalation products. Its products are used in hospitals or urgent care clinical settings.

Ratios

Current vs industry vs history
PE Ratio (TTM) 411.20
PE Ratio ranked lower than
100.00% of 557 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1910, Med: 23.77, Min: 0.06
AMPH: 411.2
Ranked among companies with meaningful PE Ratio only.
PE Ratio range over the past 10 years
Min: 38.53, Med: 208.92, Max: 99999999.99
Current: 411.2
38.53
99999999.99
PE Ratio without NRI 411.20
PE without NRI ranked lower than
100.00% of 556 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 2125, Med: 24.2, Min: 0.06
AMPH: 411.2
Ranked among companies with meaningful PE without NRI only.
PE without NRI range over the past 10 years
Min: 38.53, Med: 208.92, Max: 99999999.99
Current: 411.2
38.53
99999999.99
PB Ratio 3.08
PB Ratio ranked higher than
52.38% of 819 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 227.39, Med: 2.64, Min: 0.05
AMPH: 3.08
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 1.33, Med: 2.41, Max: 3.8
Current: 3.08
1.33
3.8
PS Ratio 3.09
PS Ratio ranked lower than
54.06% of 775 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 9105.26, Med: 3.1, Min: 0.03
AMPH: 3.09
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 0.53, Med: 3.08, Max: 3.95
Current: 3.09
0.53
3.95
Price-to-Operating-Cash-Flow 36.83
Price-to-Operating-Cash-Flow ranked lower than
70.41% of 392 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 14229.87, Med: 22, Min: 0.23
AMPH: 36.83
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 8, Med: 24.97, Max: 62.95
Current: 36.83
8
62.95
EV-to-EBIT -228.77
EV-to-EBIT ranked lower than
100.00% of 572 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1015380.11, Med: 17.85, Min: 0.13
AMPH: -228.77
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -2976.1, Med: -30.3, Max: 1051.8
Current: -228.77
-2976.1
1051.8
EV-to-EBITDA 76.70
EV-to-EBITDA ranked lower than
100.00% of 597 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 341528.02, Med: 15.24, Min: 0.12
AMPH: 76.7
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -194.5, Med: 38.1, Max: 2098
Current: 76.7
-194.5
2098
EV-to-Revenue 3.13
EV-to-Revenue ranked higher than
51.32% of 795 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 23858.8, Med: 3.24, Min: 0.03
AMPH: 3.13
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 1.6, Med: 3, Max: 4.1
Current: 3.13
1.6
4.1
Current Ratio 2.06
Current Ratio ranked higher than
50.76% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 413.44, Med: 2.39, Min: 0.02
AMPH: 2.06
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 1.94, Med: 2.79, Max: 3.81
Current: 2.06
1.94
3.81
Quick Ratio 1.35
Quick Ratio ranked lower than
57.54% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 413.44, Med: 1.87, Min: 0.02
AMPH: 1.35
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 1.24, Med: 1.64, Max: 2.02
Current: 1.35
1.24
2.02
Days Inventory 126.41
Days Inventory ranked lower than
63.31% of 755 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 950.68, Med: 119.8, Min: 0.2
AMPH: 126.41
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 82.24, Med: 160.31, Max: 181.84
Current: 126.41
82.24
181.84
Days Sales Outstanding 63.43
Days Sales Outstanding ranked higher than
68.96% of 770 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 864.61, Med: 81.76, Min: 0.1
AMPH: 63.43
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 38.3, Med: 48.23, Max: 65.04
Current: 63.43
38.3
65.04
Days Payable 64.13
Days Payable ranked higher than
77.84% of 758 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 952.38, Med: 76.32, Min: 0.04
AMPH: 64.13
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 23.3, Med: 48.19, Max: 64.13
Current: 64.13
23.3
64.13

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -0.90
3-Year Share Buyback Rate ranked higher than
71.10% of 571 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 100, Med: -5.3, Min: -815
AMPH: -0.9
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -79.5, Med: -77.4, Max: -0.9
Current: -0.9
-79.5
-0.9

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 3.54
Price-to-Tangible-Book ranked higher than
56.07% of 749 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 972.22, Med: 3.33, Min: 0.05
AMPH: 3.54
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 1.75, Med: 2.84, Max: 3.63
Current: 3.54
1.75
3.63
Price-to-Projected-FCF 3.71
Price-to-Intrinsic-Value-Projected-FCF ranked lower than
100.00% of 374 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 209, Med: 2.11, Min: 0.05
AMPH: 3.71
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 2.5, Med: 3.15, Max: 3.81
Current: 3.71
2.5
3.81
Price-to-Median-PS-Value 1.01
Price-to-Median-PS-Value ranked lower than
65.81% of 743 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 238.36, Med: 0.94, Min: 0.01
AMPH: 1.01
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.2, Med: 0.98, Max: 1.25
Current: 1.01
0.2
1.25
Price-to-Graham-Number 8.03
Price-to-Graham-Number ranked lower than
100.00% of 481 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 36.65, Med: 1.81, Min: 0.02
AMPH: 8.03
Ranked among companies with meaningful Price-to-Graham-Number only.
Price-to-Graham-Number range over the past 10 years
Min: 2.43, Med: 5.35, Max: 33.75
Current: 8.03
2.43
33.75
Earnings Yield (Joel Greenblatt) % -0.44
Earnings Yield (Greenblatt) ranked lower than
71.63% of 867 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 769.23, Med: 3.31, Min: -333.33
AMPH: -0.44
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -5.3, Med: -0.9, Max: 3.9
Current: -0.44
-5.3
3.9

More Statistics

Revenue (TTM) (Mil) $ 316.06
EPS (TTM) $ 0.05
Beta 1.06
Volatility % 41.07
52-Week Range $ 15.04 - 25.43
Shares Outstanding (Mil) 47.07

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 7
Positive ROA Y
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy Y